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Abstract
Background: Meningiomas are the most common central nervous system tumor. We describe 
current trends in treatment and survival using the largest cancer dataset in the United States.
Methods: We analyzed the National Cancer Database from 2004–2014, for all patients with 
diagnosis of meningioma.
Results: 201,765 cases were analyzed. Patients were most commonly White (81.9%) females 
(73.2%) with a median age of 64 years. Fifty percent of patients were diagnosed by imaging. 
Patients were reported as grade I (24.9%), grade II (5.0%), grade III (0.7%), or unknown WHO 
grade (69.4%). Patients diagnosed by imaging were older, received treatment in community 
facilities, had higher Charlson-Deyo score, and a lower rate of private insurance. Watchful waiting 
was the most common treatment modality (46.7%), followed by surgery only (40%). Grade II and 
III patients were more likely to receive therapy. Watchful waiting increased from 35.2% in 2004 to 
51.4% in 2014. Younger age, male gender, private insurance, and treatment in academic facilities 
were determinants for receipt of surgery and/or radiation. Median survival was 12.6 years, higher 
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in histologically confirmed cases (13.1 years). Older patients, Blacks, males, those that received 
radiation and surgery, and were treated in community facilities had an increased risk of mortality.
Conclusions: Over half of patients were diagnosed by imaging, suggesting a higher role of 
clinical determinants over histological confirmation in treatment decisions. Watchful waiting as 
initial management is increasing. Our survival analysis favored histological confirmation. Patients 
receiving radiation and surgery had an increased risk of mortality.
Keywords
Meningiomas; National Cancer Database; Outcomes; survival; treatment
INTRODUCTION
Meningiomas are the most common central nervous system tumor with an incidence rate of 
8.14/100,000 population from 2010–2014 in the United States [1]. Most meningiomas are 
benign, slow-growing, but with a consistent pattern of increasing incidence [2]. 
Meningiomas are classified based on morphologic criteria by the World Health Organization 
(WHO) into three groups (grade I-III) [3]. Tissue confirmation may be deferred in some 
patients, as meningiomas can be diagnosed by imaging [4, 5], and are frequently diagnosed 
incidentally. In those cases, magnetic resonance imaging may be used to differentiate benign 
and atypical meningioma, based on tumor margins, edema, bone destruction, and diffusion 
coefficient [6, 7]. Population-based studies estimate that around 90% are grade I (benign), 
10% are grade II (borderline), and less than 3% are grade III (malignant) [1, 8].
Treatment approaches for meningiomas include either observation alone, radiation alone, or 
surgical resection with or without radiation, and rarely, in cases with progression, a trial of 
systemic treatment, although there are no FDA approved therapies. Patients may be treated 
conservatively in small, asymptomatic tumors, whereas radiation therapy is reserved to 
prevent further growth in high grade lesions or in cases where a complete resection cannot 
be performed [9], with limited level 1 evidence on treatment recommendations.
An early investigation using the National Cancer Database (NCDB) included cases from 
1985 to 1988 and 1990 to 1992 [10]. Subsequent analyses of the NCDB focused on 
discussions of high-grade meningiomas [9, 11–13] and limited their cohorts to patients with 
surgical or histological confirmation; these investigations may not be representative of 
treatment or decision estimates of all patients with diagnosis of meningioma. In addition, a 
recent NCDB analysis focused on grade I intracranial meningiomas that included cases 
without WHO grade as grade I [14]. Data on the accuracy of imaging alone in determining 
WHO grade is limited [6, 7], and many of the patients without WHO grade reported may 
have had grade II or III disease, inconclusive pathology reports, contraindications, or refused 
to undergo biopsy or surgery. We provide an overall estimate on initial treatment decisions 
along with survival estimates for meningiomas in the United States.
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METHODS
We analyzed the NCDB from 2004–2014, for patients with diagnosis of meningioma using 
International Classification of Disease for Oncology (ICD-O-3) codes 9530–9534 and 9537–
9539. The NCDB prospectively collects cancer patient data from over 1,500 American 
College of Surgeons Commission on Cancer (CoC) accredited institutions in the United 
States [15–18].
Data in our analysis includes age at diagnosis, sex, race, Hispanic origin, comorbidities 
based on Charlson-Deyo score (CDS) [19], primary payer status, median income, education 
status (percentage of non-High school graduates), and residency area, as defined by the 
United States Department of Agriculture Economic Research Service based on the patient’s 
residential zip code. Facility type was included as available, with community facilities 
defined as centers without graduate medical education.
Patients were divided into grade I, II, III, or unknown using the “cs_site_specific_factor_1,” 
which codes WHO grade as stated in the pathology report. Treatment received was assessed 
as first course of treatment at any CoC facility. Treatment groups included: 1) surgery, 2) 
radiation, 3) chemotherapy; 4); radiation and chemotherapy; 5) radiation and surgery; 6) 
chemotherapy and surgery; 7) radiation, chemotherapy, and surgery; 8) no treatment 
(watchful waiting); and 9) unknown. No treatment (watchful waiting) was defined as not 
receiving radiation, chemotherapy, or surgery. Further lines of therapy and recurrence rate 
are not captured by the database and were therefore not considered for the study. Living 
region was defined as metropolitan (population of 250,000 or more), urban (2,500 to less 
than 250,000), and rural (less than 2,500).
Medians and inter-quartile ranges are presented for continuous variables and compared using 
Wilcoxon Rank Sum tests. For categorical variables, counts and percentages are presented 
and compared using chi-square tests. Kaplan Meier was employed to assess survival. Cox 
proportional hazards models were used to assess risk factors for mortality and receipt of 
treatment (surgery or radiation). The level of statistical significance was set at 0.05 for all 
tests conducted, and all analyses were performed with SAS software version 9.4 (SAS 
Statistical Institute, Cary, North Carolina).
RESULTS
A total of 201,765 cases of meningiomas were included in our analysis, with a female 
gender predominance (73.2%). The median age was 64 (53–76) years, with 10.9% of 
patients younger than 44 years of age, 39.2% between 45 and 64 years, 21.9% between 65 
and 74 years, and 28% older than 75 years of age. The most common race was White 
(81.9%), followed by Black (12.2%), and Other (4.3%); 6.2% were of Hispanic origin. The 
racial and ethnic distribution represent a significant variation compared to the United States 
population, where Whites account for 62%, Blacks for 12.6%, and 17.3% are Hispanic [20]. 
Tumor location in the spine was reported in 1,054 (0.5%) patients.
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Diagnostic confirmation.
Fifty percent of the patients were diagnosed by clinical and imaging criteria (n=101,586), 
while 49.3% (N=99,447) were confirmed histologically. Diagnosis confirmation was 
unknown in 732 patients. Patients diagnosed by clinical and imaging criteria were 
significantly older (median of 71 years) compared to patients diagnosed histologically 
(median of 59 years), were more commonly seen in community hospitals (50.4% versus 
34.8%), had a slightly higher percentage of ≥3 of CDS (3.6% versus 2.4%), had a lower 
frequency of private insurance (29.5% versus 50.3%), and a higher percentage of patients 
covered by Medicare (58.8% versus 34.7%). We found no differences in gender, race, 
Hispanic origin, urban/rural status, education, or median income while comparing patients 
diagnosed by clinical and imaging criteria to those diagnosed with histological confirmation. 
In the clinical and imaging group 86.2% received no treatment, 10.5% received radiation, 
and 0.2% underwent any kind of surgery.
WHO Grade.
Overall, WHO grade was reported in 30.6% of the cases. Of these, grade I was reported in 
50,282 (81.4%), grade II in 10,183 (16.5%), and grade III in 1,337 (2.2%). CDS was found 
to be zero in 73.3% of the patients, remaining constant among grades. Grade I patients were 
significantly younger (median age of 58 years) and had a female gender predominance 
(73.2%). Grade II and III patients were significantly older (age 60 and 64, respectively), and 
had a higher proportion of males (43.0% and 48.9%, respectively). White race was the most 
common in all groups, however grade II meningiomas had a higher frequency of Black 
patients. Hispanic origin remained constant among groups.
Treatment.
Overall, 46.7% received no treatment, 44.8% underwent surgery, 9.6% received radiation, 
0.5% received hormone therapy, and 0.2% received chemotherapy. Over 40% of patients 
were treated with surgery only (table 1, figure 1). In grade III patients, 42.1% received 
surgery only, as compared to 86.4% of grade I, and 72.7% of grade II. Grade II and III 
patients were more likely to receive radiation (22.9% and 51.1%, respectively), and 
chemotherapy (0.3% and 6.2%, respectively) compared to grade I patients.
Surgery.
The extent of surgical resection was reported in 46.8% of patients. Of these, gross total 
resection was performed in 51.9%. The frequency of gross total resection increased with 
grade and was highest in patients with anaplastic meningioma (59%). Younger age, male 
gender, other race, Hispanic origin, private insurance, and treatment in an academic facility 
were identified as factors for receiving surgery (supplemental table 1).
Radiation.
The majority of patients received radiation after surgery (N=7,135; 97.9%). The sequence of 
radiation and surgery did not vary by WHO grade. The most common type of radiation was 
stereotactic radiosurgery (SRS), accounting for 55.3% of patients that received radiation, 
followed by external beam (43.4%). Grade II and III patients were more likely to receive 
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external beam radiation, while in patients without reported grade, SRS was the most 
common type of radiation. In grade I, external beam radiation was used slightly more than 
SRS (table 1). Older age, female gender, Hispanic origin, treatment in a community facility, 
and not having insurance were identified as factors for receiving radiation (supplemental 
table 2).
Year of diagnosis.
The type of treatment received varied significantly with each year of diagnosis. Watchful 
waiting increased significantly during the timeframe, from 35.2% to 51.4% (2004–2014). 
The use of radiation only and surgery only decreased progressively with more recent years 
of diagnosis (supplemental table 3).
Socio-economic characteristics.
The type of CoC facility was reported in 93% of the cases. Patients were treated in 
community facilities (42.8%), academic hospitals (37.8%), or integrated network hospitals 
(12.4%). Grade III meningioma patients were more likely to be treated in community 
settings (34.1%), compared to 30.1% of grade I, and 27.9% of grade II. Patients living in 
metropolitan areas accounted for 82.8% of the cohort, and 14.2% lived in urban/rural areas, 
remaining constant between WHO grade groups. Fifty-seven percent of patients lived in 
areas with <12.9% of non-high school graduates. Overall, the most common type of 
insurance was Medicare (46.9%), followed by private insurance (39.8%). Medicare was 
more frequent in patients with anaplastic meningiomas. The majority of patients (60.2%) 
had an annual income higher than $48,000 per year. Socioeconomic factors did not vary by 
WHO grade.
Survival.
Median survival was 12.6 years overall. Survival varied significantly by WHO grade; was 
11.9 years in grade II, 11.7 years in patients without grade reported, and 4.7 years in grade 
III (figure 2). Median survival could not be assessed in grade I as the survival rates were 
higher than 50% at the end of the follow-up period. Survival estimates were higher for 
younger patients, females, and non-Hispanics (table 2). Histological diagnostic confirmation 
was also associated with higher median survival (13.1 years) compared to patients diagnosed 
by clinical/imaging criteria (9.3 years) (figure 3). Patients that received surgery had 5-year 
survival estimates over 86%, compared to 82.5% for patients that received radiation, 64.9% 
for patients who did not receive treatment, and 48.2% for patients that received 
chemotherapy.
Kaplan Meier survival estimates were assessed by type of radiation received; patients that 
underwent SRS were found to have higher survival estimates compared to external beam 
radiation in the overall population. Older age, Black race, male gender, receiving surgery 
plus radiation, and treatment in a community facility were identified as risk factors for 
mortality (table 3). Private insurance and overall higher socioeconomic status were 
protective factors for mortality.
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DISCUSSION
We provide a comprehensive analysis on patterns of care for meningiomas in the United 
States. This is important in a disease with an increasing incidence and long-term survival 
[8]. Over 50% of patients were diagnosed by clinical/imaging modalities alone, and 46.7% 
did not receive initial therapy. Survival has increased in comparison with previous studies, 
and our findings emphasize the role of clinical determinants in treatment decisions compared 
to histological confirmation or WHO grade.
NCDB is a valuable resource for long-term survival estimates, as it is one of the major 
sources for cancer care improvement [21]. One previous NCDB study presented an overall 
assessment of meningiomas and was published prior to wide use of modern imaging 
techniques [10]. Recent descriptions excluded patients without histological confirmation, or 
focused on specific and uncommon histological subgroups [10–14], limiting their findings to 
a selective patient population.
In our study, watchful waiting was the most common treatment modality (46.7%), followed 
by surgery only. The use of watchful waiting increased progressively with each diagnosis 
year, as previously reported in an NCDB study for grade I intracranial meningioma [14]. 
Watchful waiting is an option for asymptomatic tumors, generally <3cm; deferring surgical 
treatment until documentation on the pace of tumor growth [22, 23]. This correlates with 
50% of patients that were diagnosed by imaging, and the large number of patients without 
reported WHO grade, as meningiomas can be diagnosed incidentally or may be located in 
surgically challenging areas, such as the posterior fossa [5]. A strength of this study is the 
inclusion of patients without WHO grade reported along with a separate description of their 
outcomes and characteristics, reflecting common clinical practice scenario.
Patients without a reported WHO grade may be considered low-risk based on imaging and 
clinical examination, and over 65% of these patients were followed expectantly. These 
patients had a similar survival compared to grade II meningiomas in our cohort (figure 2). 
This group was also significantly older compared to grade I, and a had a higher number of 
patients with a CDS ≥3. Previous NCDB investigations grouped these patients as WHO 
grade I, reporting 50% not receiving initial therapy [14]. Imaging alone is not sufficient to 
establish grade; other reasons, including non-resectable tumors, inconclusive pathology 
reports, and contraindications for surgery, may play a role in the decision. From our analysis, 
4.8% of grade I patients and 65.5% of patients with unknown grade did not receive initial 
treatment. Overall, the poorer outcomes of patients diagnosed by imaging only can be 
explained by older age, higher number of comorbidities, and possibly having locations or 
number of lesions preventing tissue confirmation. In addition, dural–based mesenchymal 
neoplasms, or dural metastases may mimic meningiomas by imaging [24].
The 5-year survival estimates were higher in patients that underwent surgical resection 
compared to those that did not receive treatment. However, a multivariate analysis did not 
confirm differences in overall mortality risk while comparing surgical resection alone to 
watchful waiting. Tumor growth is expected in patients that are followed expectantly and the 
decision to undergo surgery is based on degree of extension, proximity to critical central 
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nervous system locations, irresectability or other contraindications for surgery [25], 
therefore the observed 5-year survival differences may be explained by patient selection 
alone (for surgery).
The use of radiation plus surgery was associated with mortality, as it is expected that patients 
who receive this treatment have higher grade lesions or non-resectable tumors. The use of 
radiation after surgery for grade II and III meningiomas has shown positive results, in a non-
randomized clinical trial [26], with results still to be finalized by the European Organization 
for Research and Treatment of Cancer (EORTC). The majority of data that supports this 
approach comes from retrospective analyses [27, 28], including previous NCDB descriptions 
of aggressive meningiomas (anaplastic and papillary) [11, 12], which may explain the 
differences in practice patterns with less than 23% of grade II and 51.1% of grade III tumors 
reporting its use. Interestingly, an NCDB investigation for atypical meningiomas showed an 
age related benefit of radiation (<55 years and >75 years) [9]. Older age was a risk factor for 
mortality in our analysis, and was also a protective factor for receiving radiation, markedly 
between 65 and 74 years of age.
Radiation only may be used in non-resectable tumors, particularly in skull base, or optic 
nerve sheath meningiomas, and in elderly patients where retrospective analyses have 
demonstrated benefit [9, 29, 30]. Stereotactic radiosurgery and hypofractionated radiation 
alone have shown five-year tumor control rates over 84% [31–33]. In our analysis, the most 
common type of radiation was SRS, and was more common in patients without reported 
WHO grade. External beam radiation was most common in grade II and III, and survival of 
these patients was decreased compared to SRS. This could be for many reasons, including 
patient selection bias for the more technologically advanced SRS, size and number of 
lesions, limitations in SRS tumor treatment compared to external beam radiation, and 
possibly as an indicator of higher quality care facility.
Hormone therapy was used in 1,094 patients, representing 0.5% of the cohort and was 
associated with increased mortality. This is at least partially explained because it is offered 
in patients with limited therapeutic options. The female predominance in benign 
meningioma and link to breast cancer suggests a possible sex hormone dependency tied to 
the growth of these tumors [34, 35]. However, no therapeutic benefit has been found by 
targeting sex hormone receptors in clinical trials [36, 37]. Somatostatin analogs initially 
showed benefits in case reports [38], but failed to be verified in clinical trials [39, 40].
Median survival was 12.6 years, and 5-year survival rates were 88.3% for grade I, 78.8% for 
grade II, 48.7% for grade III, and 71.9% for tumors without a reported WHO grade. This 
demonstrates an increased survival for meningiomas from that reported in previous analyses 
[10, 41]. Interestingly, the survival in grade I and II meningiomas is higher than reported in 
previous NCDB analyses excluding imaging based diagnosed cases, but lower for grade III 
(85.5%, 75.9%, and 55.4%, respectively) [13].
Patients with grade III meningiomas were more likely to receive adjuvant therapy, with 6.2% 
receiving chemotherapy as first course treatment although there is no Food and Drug 
Administration (FDA) approved chemotherapy. This is slightly smaller than the 7% 
Garcia et al. Page 7
Cancer Epidemiol. Author manuscript; available in PMC 2020 June 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
previously described [11], and is in keeping with the literature as chemotherapy has not 
shown survival benefits in meningiomas.
Treatment with chemotherapy only (without surgery or radiation therapy) showed the lowest 
5-year survival rates (32.7%). This lower survival is expected as chemotherapy is used in 
cases of surgically inaccessible tumors and in patients who cannot receive further radiation 
therapy [42]. Hydroxyurea was dropped from the National Comprehensive Cancer Network 
(NCCN) guideline for WHO grade II meningiomas starting in 2009, based on the lack of 
survival benefits [42]. The only systemic therapies that have shown limited efficacy are 
somatostatin analogues, sunitinib, bevacizumab, everolimus, and interferon-alpha at 
recurrence [43–45]. Immunotherapy with immune checkpoint inhibitors may have a role in 
the future as evidence demonstrates PD-L1 expression in anaplastic meningiomas [46].
The main limitations of our study include the inability to evaluate cause of death, recurrence 
rate, individual patient characteristics, overall performance, further treatment lines, and the 
reasons behind treatment decisions. Our analysis provides a large-scale evaluation of the 
treatment and survival patterns of meningiomas in the United States, and highlights the 
increasing survival of meningiomas and the large number of cases diagnosed by imaging 
only. We believe our combined assessment provides a real-world picture of treatment and 
survival patterns of meningiomas, as treatment decisions are made before pathological 
confirmation. The observed 5-year survival differences between watchful waiting and 
surgery only, along with the use of chemotherapy in anaplastic lesions calls for prospective 
evaluations and the need for development of further systemic treatment approaches in 
patients with aggressive tumors or contraindications for surgery.
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HIGHLIGHTS
• We describe current trends in treatment and survival using the largest clinical 
cancer dataset
• Over fifty percent of meningiomas were diagnosed by imaging
• Watchful waiting was the most common treatment modality, followed by 
surgery only
• Older patients, blacks, males, and community facilities had a higher risk of 
mortality
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Figure 1. 
Summary of treatment receipt overall and by WHO grade
Garcia et al. Page 13
Cancer Epidemiol. Author manuscript; available in PMC 2020 June 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Figure 2. 
Survival by WHO grade (p<0.001)
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Figure 3. 
Survival by type of diagnostic confirmation (p<0.001)
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Table 1.
Demographics and clinical characteristics of meningiomas, NCDB 2004–2014.
Grade I N=50282 Grade II N=10183 Grade III N=1337 Not Stated N=139963 All N=201765
Age in Years (median, 
range)
58 (48 – 68) 60 (48 – 70) 64 (52 – 74) 67 (55 – 79) 64 (53 – 76)
Gender Male 13517 (26.9%) 4375 (43.0%) 654 (48.9%) 35503 (25.4%) 54049 (26.8%)
Female 36765 (73.1%) 5808 (57.0%) 683 (51.1%) 104460 (74.6%) 147716 (73.2%)
Race Unknown 857 (1.7%) 135 (1.3%) 22 (1.6%) 2091 (1.5%) 3105 (1.5%)
White 40908 (81.4%) 7986 (78.4%) 1081 (80.9%) 115329 (82.4%) 165304 (81.9%)
Black 5985 (11.9%) 1536 (15.1%) 173 (12.9%) 16919 (12.1%) 24613 (12.2%)
Other 2532 (5.0%) 526 (5.2%) 61 (4.6%) 5624 (4.0%) 8743 (4.3%)
Hispanic Origin Unknown 2837 (5.6%) 633 (6.2%) 77 (5.8%) 8146 (5.8%) 11693 (5.8%)
No 44014 (87.5%) 8905 (87.4%) 1169 (87.4%) 123386 (88.2%) 177474 (88.0%)
Yes 3431 (6.8%) 645 (6.3%) 91 (6.8%) 8431 (6.0%) 12598 (6.2%)
Diagnostic Confirmation Unknown 32 (0.1%) 1 (0.0%) 1 (0.1%) 698 (0.5%) 732 (0.4%)
Histology 48473 (96.4%) 10128 (99.5%) 1308 (97.8%) 39538 (28.2%) 99447 (49.3%)
Clinical/Imaging 1777 (3.5%) 54 (0.5%) 28 (2.0%) 99727 (71.2%) 101586 (50.3%)
Charlson-Deyo Score 0 37175 (73.9%) 7223 (70.9%) 944 (70.6%) 102535 (73.3%) 147877 (73.3%)
1 9167 (18.2%) 1922 (18.9%) 252 (18.8%) 24333 (17.4%) 35674 (17.7%)
2 2759 (5.5%) 688 (6.8%) 95 (7.1%) 8539 (6.1%) 12081 (6.0%)
≥3 1181 (2.3%) 350 (3.4%) 46 (3.4%) 4556 (3.3%) 6133 (3.0%)
Facility Type Unknown 5095 (10.1%) 1286 (12.6%) 122 (9.1%) 7690 (5.5%) 14193 (7.0%)
Community 15158 (30.1%) 2843 (27.9%) 456 (34.1%) 67835 (48.5%) 86292 (42.8%)
Academic 23948 (47.6%) 4821 (47.3%) 599 (44.8%) 46951 (33.5%) 76319 (37.8%)
Integrated Network 6081 (12.1%) 1233 (12.1%) 160 (12.0%) 17487 (12.5%) 24961 (12.4%)
Type of insurance Not Insured 2203 (4.4%) 588 (5.8%) 53 (4.0%) 5165 (3.7%) 8009 (4.0%)
Private Insurance 26015 (51.7%) 4732 (46.5%) 558 (41.7%) 48946 (35.0%) 80251 (39.8%)
Medicaid 3683 (7.3%) 877 (8.6%) 90 (6.7%) 7575 (5.4%) 12225 (6.1%)
Medicare 16567 (32.9%) 3680 (36.1%) 591 (44.2%) 73741 (52.7%) 94579 (46.9%)
Other Government 716 (1.4%) 152 (1.5%) 24 (1.8%) 1357 (1.0%) 2249 (1.1%)
Insurance Status Unknown 1098 (2.2%) 154 (1.5%) 21 (1.6%) 3179 (2.3%) 4452 (2.2%)
Median Income 
Quartiles 2007–2012
Unknown 348 (0.7%) 78 (0.8%) 21 (1.6%) 1473 (1.1%) 1920 (1.0%)
<$38,000 8318 (16.5%) 1807 (17.7%) 237 (17.7%) 24146 (17.3%) 34508 (17.1%)
$38,000-$47,999 11254 (22.4%) 2354 (23.1%) 318 (23.8%) 32146 (23.0%) 46072 (22.8%)
$48,000-$62,999 13434 (26.7%) 2694 (26.5%) 336 (25.1%) 37729 (27.0%) 54193 (26.9%)
≥$68,000 16928 (33.7%) 3250 (31.9%) 425 (31.8%) 44469 (31.8%) 65072 (32.3%)
Percent No High School 
Degree 2007–2012
Unknown 327 (0.7%) 71 (0.7%) 20 (1.5%) 1412 (1.0%) 1830 (0.9%)
≥21% 8335 (16.6%) 1769 (17.4%) 231 (17.3%) 24180 (17.3%) 34515 (17.1%)
13.0–20.9% 12780 (25.4%) 2552 (25.1%) 351 (26.3%) 35302 (25.2%) 50985 (25.3%)
7.0–12.9% 16058 (31.9%) 3263 (32.0%) 395 (29.5%) 44553 (31.8%) 64269 (31.9%)
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Grade I N=50282 Grade II N=10183 Grade III N=1337 Not Stated N=139963 All N=201765
<7.0% 12782 (25.4%) 2528 (24.8%) 340 (25.4%) 34516 (24.7%) 50166 (24.9%)
Living Area Unknown 1283 (2.6%) 272 (2.7%) 54 (4.0%) 4497 (3.2%) 6106 (3.0%)
Metro 41287 (82.1%) 8271 (81.2%) 1064 (79.6%) 116487 (83.2%) 167109 (82.8%)
Urban 5563 (11.1%) 1193 (11.7%) 157 (11.7%) 13645 (9.7%) 20558 (10.2%)
Rural 2149 (4.3%) 447 (4.4%) 62 (4.6%) 5334 (3.8%) 7992 (4.0%)
Surgery Unknown 917 (1.8%) 241 (2.4%) 27 (2.0%) 1453 (1.0%) 2638 (1.3%)
None 2908 (5.8%) 236 (2.3%) 64 (4.8%) 105531 (75.4%) 108739 (53.9%)
Yes 46457 (92.4%) 9706 (95.3%) 1246 (93.2%) 32979 (23.6%) 90388 (44.8%)
Radiation Unknown 555 (1.1%) 95 (0.9%) 16 (1.2%) 1568 (1.1%) 2234 (1.1%)
No 47000 (93.5%) 7759 (76.2%) 638 (47.7%) 124794 (89.2%) 180191 (89.3%)
Yes 2727 (5.4%) 2329 (22.9%) 683 (51.1%) 13601 (9.7%) 19340 (9.6%)
Chemotherapy Unknown 1455 (2.9%) 296 (2.9%) 53 (4.0%) 3805 (2.7%) 5609 (2.8%)
No 48783 (97.0%) 9852 (96.7%) 1201 (89.8%) 136004 (97.2%) 195840 (97.1%)
Yes 44 (0.1%) 35 (0.3%) 83 (6.2%) 154 (0.1%) 316 (0.2%)
Treatment Summary Unknown 1729 (3.4%) 343 (3.4%) 58 (4.3%) 4944 (3.5%) 7074 (3.5%)
None 2432 (4.8%) 162 (1.6%) 44 (3.3%) 91687 (65.5%) 94325 (46.7%)
RT+CT+S 11 (0.0%) 20 (0.2%) 63 (4.7%) 34 (0.0%) 128 (0.1%)
RT+CT 4 (0.0%) 1 (0.0%) 4 (0.3%) 22 (0.0%) 31 (0.0%)
RT+S 2232 (4.4%) 2176 (21.4%) 576 (43.1%) 1970 (1.4%) 6954 (3.4%)
CT+S 27 (0.1%) 12 (0.1%) 14 (1.0%) 26 (0.0%) 79 (0.0%)
Surgery only 43433 (86.4%) 7404 (72.7%) 563 (42.1%) 29989 (21.4%) 81389 (40.3%)
RT Only 412 (0.8%) 63 (0.6%) 14 (1.0%) 11222 (8.0%) 11711 (5.8%)
CT Only 2 (0.0%) 2 (0.0%) 1 (0.1%) 69 (0.0%) 74 (0.0%)
RT: Radiation; CT: Chemotherapy; S: Surgery
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Table 2.
5-year survival estimates by selected characteristics for meningiomas, NCDB 2004–2014.
# Cases* 5-year Survival (95% CI)
Age Group (years) 0‒44 11072 95.5% (95.2% ‒ 95.9%)
45‒64 42462 89.8% (89.6% ‒ 90.0%)
65‒74 25355 77.3% (76.8% ‒ 77.7%)
≥75 38462 48.7% (48.2% ‒ 49.2%)
Gender Female 85035 78.2% (77.9% ‒ 78.4%)
Male 32316 70.3% (69.9% ‒ 70.8%)
Race Black 14114 75.2% (74.6% ‒ 75.8%)
Other 4281 82.4% (81.4% ‒ 83.3%)
Unknown 1767 84.4% (83.0% ‒ 85.9%)
White 97189 75.7% (75.5% ‒ 76.0%)
Hispanic Origin No 102931 75.6% (75.3% ‒ 75.8%)
Unknown 8223 76.7% (75.8% ‒ 77.5%)
Yes 6197 83.4% (82.6% ‒ 84.1%)
Treatment Summary None 55684 64.9% (64.6% ‒ 65.3%)
RT Only 7099 81.9% (81.2% ‒ 82.7%)
RT+S 3874 83.7% (82.7% ‒ 84.7%)
Surgery only 46254 86.4% (86.1% ‒ 86.7%)
*
Number of patients who were alive 5 years after the diagnosis
RT: Radiation; CT: Chemotherapy; S: Surgery
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Table 3.
Multivariate analysis for risk factors for mortality in meningiomas, NCDB 2004–2014.
Hazard Ratio 95% Hazard Ratio Confidence Limits
Age Group (years) ≥75 8.257 7.482 9.112
45–64 1.809 1.642 1.993
65–74 3.403 3.083 3.757
0–44 ref - -
Gender Male 1.439 1.412 1.468
Female ref - -
Race Black 1.419 1.337 1.505
Unknown 0.962 0.865 1.070
White 1.193 1.130 1.259
Other ref - -
Hispanic Origin Unknown 1.044 1.005 1.084
Yes 0.829 0.791 0.869
No ref - -
Insurance Unknown 0.916 0.834 1.006
Medicaid 1.241 1.145 1.345
Medicare 0.998 0.930 1.070
Other Government 0.973 0.861 1.099
Private Insurance 0.720 0.672 0.772
Not insured ref - -
Living Area Metro 0.965 0.922 1.011
Urban 1.017 0.965 1.072
Rural ref - -
Facility Type Community 1.125 1.102 1.148
Integrated Network 1.076 1.045 1.108
Academic ref - -
Treatment Summary CT Only 3.268 0.447 23.878
CT+S 1.792 0.241 13.298
RT Only 0.910 0.724 1.143
RT+CT 3.970 0.520 30.327
RT+CT+S 2.770 0.379 20.273
RT+S 1.365 1.052 1.773
Surgery only 1.035 0.919 1.165
Unknown 1.149 0.966 1.366
None ref - -
RT: Radiation; CT: Chemotherapy; S: Surgery
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